Gotham Asset Management’s AbCellera Biologics ABCL Stock Holding History

Gotham Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-46,090	Closed	-$298K	–	1314
2023 Q2	$298K	Sell	46,090 -77,174	-63%	-$527K	0.01%	1126
2023 Q1	$929K	Buy	123,264 +7,162	+6%	+$65K	0.02%	770
2022 Q4	$1.18M	Buy	116,102 +37,464	+48%	+$433K	0.03%	623
2022 Q3	$778K	Buy	+78,638	New	+$863K	0.02%	736
2022 Q1	–	Sell	-28,415	Closed	-$406K	–	1114
2021 Q4	$406K	Sell	28,415 -44,652	-61%	-$678K	0.01%	847
2021 Q3	$1.46M	Buy	73,067 +47,579	+187%	+$841K	0.06%	382
2021 Q2	$561K	Buy	+25,488	New	+$703K	0.02%	653

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Gotham Asset Management's ABCL Position: Q3 2023 in Review

Gotham Asset Management sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 46,090 shares — an estimated $298K sold.

Gotham Asset Management first reported a position in ABCL in Q2 2021 and held it in 7 quarters. The position peaked at $1.46M in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

Gotham Asset Management reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
Gotham Asset Management sold 46,090 AbCellera Biologics shares in Q3 2023, an estimated $298K.
Gotham Asset Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 7 quarters.
Gotham Asset Management's AbCellera Biologics position peaked at $1.46M in Q3 2021.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Gotham Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.